Recent Updates
Recently added Catalysts
WWB Positive Sentiment

Windward Bio to Participate at the Jefferies London Global Healthcare Conference

Key Takeaway: Windward Bio Group AG will present at the Jefferies London Global Healthcare Conference on November 18, 2026. The company develops ultra-long-acting antibody medicines for serious respiratory and dermatologic diseases. Its lead candidate, WIN378, is currently in Phase 2/3 trials for severe uncontrolled asthma and Phase 2 for COPD.

Market Sentiment Analysis

POSITIVE FACTORS

  • Windward Bio will present at a major healthcare conference.
  • The company is developing innovative antibody medicines.
  • Their lead candidate is in advanced clinical trials.
  • Windward focuses on serious respiratory and dermatologic diseases.

Full Press Release Details

BASEL, Switzerland, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG ("Windward") (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced that members of management will present at the Jefferies London Global Healthcare Conference on Wednesday, November 18, 2026, at 8:30 a.m.GMT.
A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Windward Bio website.

About Windward Bio Group AG

Windward (Nasdaq: WWB) is a global, clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead product candidate, WIN378, is a fully human monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and is being evaluated in the POLARIS-1 Phase 2/3 study in severe uncontrolled asthma and the SIRIUS Phase 2 study in COPD. Windward’s second product candidate, WIN027, is an ultra-long-acting bispecific antibody targeting TSLP and interleukin-13 (IL-13) and is currently in a Phase 1 healthy volunteer study.

Frequently Asked Questions

When will Windward Bio present at the conference?

Windward Bio will present on November 18, 2026, at 8:30 a.m. GMT.

What is Windward Bio developing?

Windward Bio is developing ultra-long-acting antibody medicines.

What diseases does Windward Bio focus on?

The company focuses on respiratory and dermatologic diseases.

What is Windward's lead product candidate?

Windward's lead candidate is WIN378, targeting severe uncontrolled asthma.

Last updated: Nov 17, 2026